^
Association details:
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Dasatinib…Contraindicated mutations...T315I/A, F317L/V/I/C, or V299L